Neomycin

Aminoglycoside Antibacterial — ALIMENTARY TRACT AND METABOLISM

Key facts

Neomycin is a drug in the Aminoglycoside Antibacterial class catalogued in DrugCentral. It was first approved by the FDA in 1957. DrugCentral lists 5 molecular targets, including TRPV1, lef and LRAT. Recorded indications include Bacterial keratitis, Blepharoconjunctivitis, Corneal abrasion and Hepatic coma.

• Drug class: Aminoglycoside Antibacterial.
• Molecular targets: TRPV1, lef, LRAT and MEN1 (5 listed in DrugCentral).
• Indications: Bacterial keratitis, Blepharoconjunctivitis, Corneal abrasion, Hepatic coma and Hepatic encephalopathy and others.
• ATC code: A01AB08 (Antiinfectives and antiseptics for local oral treatment).

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (15)

• Bacterial keratitis
• Blepharoconjunctivitis
• Corneal abrasion
• Hepatic coma
• Hepatic encephalopathy
• Infective blepharitis
• Keratitis
• Mastoidectomy Cavity Infections
• Minor Bacterial Skin Infections
• Minor Skin Wound Pain
• Otitis externa
• Preoperative Bowel Preparation
• Superficial Ocular Infection
• Urinary tract infectious disease
• Uveitis

Off-label uses (2)

• Bacterial conjunctivitis
• Chronic purulent otitis media

Contraindications (46)

• Adrenal cortical hypofunction
• Atrophoderma
• Auditory Neurotoxicity
• Bacterial infection of eye
• Bullous myringitis
• Dehydration
• Diabetes mellitus
• Disorder of the 8th Cranial Nerve
• Eye infection
• Fungal ear infection
• Fungal infection of eye
• Gastrointestinal obstruction
• Hearing disorder
• Herpes simplex
• Herpes simplex dendritic keratitis
• Herpes simplex keratitis
• Herpes zoster auricularis
• Hypocalcemia
• Hypovolemia
• Infant Botulism
• Injury of eye region
• Kidney disease
• Krukenberg spindle
• Myasthenia gravis
• Neuromuscular block, function
• Ocular hypertension
• Open wound
• Open-angle glaucoma
• Parkinsonism
• Perforation of tympanic membrane
• + 16 more

Mechanism & targets

• Established pharmacologic class: Aminoglycoside Antibacterial

Molecular targets (5)

Target	Gene	Action	Activity
Transient receptor potential cation channel subfamily V member 1	TRPV1	unknown	IC50 6.40
Lethal factor	lef	unknown	Ki 6.30
Lecithin retinol acyltransferase	LRAT	unknown	IC50 4.83
Menin	MEN1	unknown	Kd 4.81
Extracellular calcium-sensing receptor	Casr	agonist	Kd 4.00

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1957-03-26	FDA	—	MONARCH PHARMS

ATC classification

ATC code	Therapeutic hierarchy
A01AB08	ALIMENTARY TRACT AND METABOLISM › STOMATOLOGICAL PREPARATIONS › STOMATOLOGICAL PREPARATIONS › Antiinfectives and antiseptics for local oral treatment
A07AA01	ALIMENTARY TRACT AND METABOLISM › ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS › INTESTINAL ANTIINFECTIVES › Antibiotics
A07AA51	ALIMENTARY TRACT AND METABOLISM › ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS › INTESTINAL ANTIINFECTIVES › Antibiotics
B05CA09	BLOOD AND BLOOD FORMING ORGANS › BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS › IRRIGATING SOLUTIONS › Antiinfectives
D06AX04	DERMATOLOGICALS › ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE › ANTIBIOTICS FOR TOPICAL USE › Other antibiotics for topical use
J01GB05	ANTIINFECTIVES FOR SYSTEMIC USE › ANTIBACTERIALS FOR SYSTEMIC USE › AMINOGLYCOSIDE ANTIBACTERIALS › Other aminoglycosides
R02AB01	RESPIRATORY SYSTEM › THROAT PREPARATIONS › THROAT PREPARATIONS › Antibiotics
S01AA03	SENSORY ORGANS › OPHTHALMOLOGICALS › ANTIINFECTIVES › Antibiotics
S02AA07	SENSORY ORGANS › OTOLOGICALS › ANTIINFECTIVES › Antiinfectives
S03AA01	SENSORY ORGANS › OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS › ANTIINFECTIVES › Antiinfectives

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

• FDA label: MT-RNR1 · Actionable PGx

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Rheumatic fever	614.5
Sciatica	574.5
Type 2 diabetes mellitus	569.8
C-reactive protein	499.4
Swollen joint count increased	496.3
C-reactive protein abnormal	490.5
Lip dry	471.5
Road traffic accident	463.3
Drug hypersensitivity	459.8
Sleep disorder due to general medical condition, insomnia type	453.0
Ill-defined disorder	452.5
Psoriatic arthropathy	395.4

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Neomycin is on its molecule page.

• Molecular formula: —
• Molecular weight: —
• CAS number: —
• InChIKey: —
• PubChem CID: 8378

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Neomycin used for?

DrugCentral lists the following indications for Neomycin: Bacterial keratitis, Blepharoconjunctivitis, Corneal abrasion, Hepatic coma, Hepatic encephalopathy, Infective blepharitis, Keratitis and Mastoidectomy Cavity Infections and others.

How does Neomycin work?

Its molecular targets in DrugCentral include TRPV1, lef, LRAT and MEN1.

When was Neomycin first approved?

Neomycin was first approved by the FDA in 1957.

What drug class does Neomycin belong to?

Neomycin is in the Aminoglycoside Antibacterial class.

Sources

• DrugCentral drug card 4247 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL3989533 — compound record and bioactivity
• PubChem CID 8378 — chemical identifiers
• DrugBank DB00994 — drug record
• FDA UNII I16QD7X297 — substance identity
• DailyMed: FDA labels for Neomycin — current prescribing information (label search)
• UniProt Q8NER1 (TRPV1) — target protein
• UniProt O95237 (LRAT) — target protein
• UniProt O00255 (MEN1) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
• PharmGKB / CPIC — pharmacogenomic label annotations

How this page is built: methodology · editorial policy & corrections.